

Phone: 800.511.5144 • Fax: 877.541.1503

**CROHN'S DISEASE AND ULCERATIVE COLITIS REFERRAL FORM**

PATIENT INFORMATION					
Patient Name:		DOB:	Sex: <input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Other:		Weight: <input type="checkbox"/> lbs. <input type="checkbox"/> kg.
SSN:	Phone:	Allergies:			
Address:		City:	State:	Zip:	
Emergency Contact:		Phone:	<input type="checkbox"/> Additional Information Attached		
PRESCRIBER INFORMATION					
Prescriber:		NPI:	DEA:	State Lic:	
Supervising Physician:			Practice Name:		
Address:		City:	State:	Zip:	
Phone:	Fax:	Key Office Contact:		Phone:	
DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT					
<b>Primary Diagnosis:</b> (ICD-10 Code & Description) <input type="checkbox"/> K50.00 <input type="checkbox"/> K50.10 <input type="checkbox"/> K50.80 <input type="checkbox"/> K50.90 Crohn's Disease <input type="checkbox"/> K51.9 Ulcerative Colitis <input type="checkbox"/> Other: _____					
<ul style="list-style-type: none"> <li>▪ Has patient been treated <i>previously</i> for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No Is patient <i>currently</i> on therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Please list medication(s) and treatment duration: _____</li> <li>▪ Will patient stop taking the above medication(s) before starting the new medication? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, how long should patient wait before starting the new medication? _____</li> <li>▪ Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): _____</li> <li>▪ Has patient received a <b>Quatiferon gold, Tspot or PPD (tuberculosis) Skin Test?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Date: _____ Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive</li> </ul>					
INSURANCE INFORMATION					
<input type="checkbox"/> Please attach front and back of patient's insurance card (medical and prescription)					
COPAY CARD ENROLLMENT					
<input type="checkbox"/> Please check if enrolling in copay card		Copay ID: _____			
PRESCRIPTION INFORMATION					
<input type="checkbox"/> <b>STC Standard Protocol</b> will include the following: (1) dispensing ordered med/dose, (2) diluent to mix and/or dilute dose, (3) flushes to flush line and anakit med (epinephrine 0.3 mg IM / 0.15 mg IM (for pediatric patients) and diphenhydramine 50 mg/mL) and (4) premeds to take 30 mins before orally (Apap 325 mg, may repeat x1, and diphenhydramine 25 mg, may repeat x1).					
<input type="checkbox"/> <b>Cimzia® 200 mg/mL Prefilled Syringe</b> <input type="checkbox"/> <b>Cimzia® 200 mg Vial</b> *Cimza Prefilled Syringes will be dispensed unless MD selects Vial. <small>*Note: Cimzia Vial should be prepared and administered by a health care professional. AcariaHealth will coordinate home care with Cimplicity™ Program.</small>					
<input type="checkbox"/> Starter Dose: 400 mg SQ (2 inj. of 200 mg) initially at Week 0, repeat at Weeks 2 and 4		<input type="checkbox"/> <b>Enroll in Cimplicity™ Program</b>			
<input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> 400 mg SQ every 4 weeks <input type="checkbox"/> 200 mg SQ every 2 weeks		QTY: <u>1 starter kit (6 PFS)</u> Refills: <u>0</u>		QTY: <u>1 box (2 x 200 mg)</u> Refills: _____	
<input type="checkbox"/> <b>Entyvio® 300 mg Vial</b> <input type="checkbox"/> MD's Office Infusion <input type="checkbox"/> Home Infusion Supplies					
<input type="checkbox"/> Starter Dose: 300 mg IV at Week 0, Week 2, Week 6		QTY: <u>3 vials</u>		Refills: <u>0</u>	
<input type="checkbox"/> Maintenance Dose: 300 mg IV every 8 weeks		QTY: <u>1 vial</u>		Refills: _____	
<input type="checkbox"/> <b>Humira® Starter Package CF 80 mg / 0.8 mL Pen NDC: 0074-0124-03</b>					
Starter Dose: <input type="checkbox"/> Two 80 mg SQ inj. Day 1, one 80 mg SQ inj. Day 15		<input type="checkbox"/> <b>Enroll in Humira Complete Program</b>			
<input type="checkbox"/> One 80 mg SQ inj. Day 1, one 80 mg SQ inj. Day 2, one 80 mg SQ inj. Day 15		QTY: <u>3 pens</u>		Refills: <u>0</u>	
QTY: <u>3 pens</u>		Refills: <u>0</u>			
<input type="checkbox"/> <b>Humira® CF 40 mg/0.4 mL Pen NDC: 0074-0554-02</b> <input type="checkbox"/> <b>Humira® CF 40 mg/0.4 mL Prefilled Syringe NDC: 0074-0243-02</b>					
Maintenance Dose: <input type="checkbox"/> One 40 mg SQ inj. Day 29 & every other week thereafter		QTY: <u>2</u>		Refills: _____	
<input type="checkbox"/> Alternate Dose: _____		QTY: _____		Refills: _____	
<input type="checkbox"/> <b>Remicade® 100 mg Vial</b> <input type="checkbox"/> <b>Inflectra® 100 mg Powder Vial</b> <input type="checkbox"/> <b>Renflexis® 100 mg Powder Vial</b>					
<input type="checkbox"/> MD's Office Infusion <input type="checkbox"/> Home Infusion Supplies Required		<input type="checkbox"/> <b>Enroll in AccessOneSM Program</b>			
<input type="checkbox"/> Starter Dose: _____ mg IV on Week 0, Week 2, Week 6, then _____		QTY: _____		Refills: <u>0</u>	
<input type="checkbox"/> Maintenance Dose: _____ mg IV every _____ weeks		QTY: _____		Refills: _____	
<input type="checkbox"/> <b>Rinvoq®</b>					
<input type="checkbox"/> Starter Dose: 45 mg once daily x 8 weeks		QTY: <u>28</u>		Refills: <u>1</u>	
<input type="checkbox"/> Maintenance Dose: 15 mg once daily		QTY: _____		Refills: _____	
<input type="checkbox"/> Alternate Dose: 30 mg once daily for pts w/severe, or refractory disease		QTY: _____		Refills: _____	
<input type="checkbox"/> <b>Simponi® SmartJect 100 mg/mL</b> <input type="checkbox"/> <b>Simponi® Prefilled Syringe 100 mg/mL</b> <small>Simponi SmartJect will be dispensed unless MD selects Prefilled Syringes</small>					
<input type="checkbox"/> Starter Dose: 200 mg SQ at Week 0, 100 mg at Week 2, then start maintenance at Week 6		QTY: <u>3</u>		Refills: <u>0</u>	
<input type="checkbox"/> Maintenance Dose: 100 mg SQ every 4 weeks starting at Week 6		QTY: <u>1</u>		Refills: _____	
<input type="checkbox"/> Alternate Dose: _____		QTY: _____		Refills: _____	
<input type="checkbox"/> <b>Skyrizi®</b>					
<input type="checkbox"/> Starter Dose: 600 mg IV on Week 0, Week 4, Week 8		QTY: <u>3</u>		Refills: <u>0</u>	
<input type="checkbox"/> Maintenance Dose: 360 mg SQ on week 12 and every 8 weeks thereafter		QTY: <u>1</u>		Refills: _____	

**Physician's Signature:** \_\_\_\_\_  DAW (Dispense as Written) **Date:** \_\_\_\_\_

Prescriber certifies that this referral form contains an original signature and is signed by the treating physician. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send prescription on official state prescription blank. In the event requested agent is not available through AcariaHealth, this prescription shall be forwarded to an eligible pharmacy.

**IMPORTANT NOTICE:** This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.

Phone: 800.511.5144 • Fax: 877.541.1503

**CROHN'S DISEASE AND ULCERATIVE COLITIS REFERRAL FORM**

PATIENT INFORMATION			
Patient Name:		DOB:	
Address:	City:	State:	Zip:
INSURANCE INFORMATION			
<input type="checkbox"/> Please attach front and back of patient's insurance card (medical and prescription)			
COPAY CARD ENROLLMENT			
<input type="checkbox"/> Please check if enrolling in copay card		Copay ID:	
PRESCRIPTION INFORMATION			
<input type="checkbox"/> Stelara®		<input type="checkbox"/> Enroll in Janssen CarePath Program	
<input type="checkbox"/> Induction Dose: IV Infusion 130 mg/26 mL (5 mg/mL) single-dose vial, weight-based <input type="checkbox"/> MD's Office Infusion <input type="checkbox"/> Home Infusion Supplies Required			
<input type="checkbox"/> Less than or equal to 55 kg: IV Infusion 260 mg (2 vials) once	QTY: <u>  2  </u>	Refills: <u>  0  </u>	
<input type="checkbox"/> Greater than 55 kg to 85 kg: IV Infusion 390 mg (3 vials) once	QTY: <u>  3  </u>	Refills: <u>  0  </u>	
<input type="checkbox"/> Greater than 85 kg: IV Infusion 520 mg (4 vials) once	QTY: <u>  4  </u>	Refills: <u>  0  </u>	
<input type="checkbox"/> Maintenance Dose: 90 mg/mL single-dose Prefilled Syringe <input type="checkbox"/> Home Injection Dose: SQ inj. 90 mg 8 weeks after first IV dose, every 8 weeks thereafter	QTY: <u>  1  </u>	Refills: <u>      </u>	
<input type="checkbox"/> Xeljanz® 5 mg Oral Tablet <input type="checkbox"/> Xeljanz® 10 mg Oral Tablet		QTY: _____ Refills: _____	
<input type="checkbox"/> Starter Dose: Twice daily		QTY: _____ Refills: _____	
<input type="checkbox"/> Other _____		QTY: _____ Refills: _____	
<input type="checkbox"/> Xeljanz XR® 11 mg Oral Tablet <input type="checkbox"/> Xeljanz XR® 22 mg Oral Tablet		QTY: <u>  30  </u> Refills: _____	
<input type="checkbox"/> Starter Dose: Once daily		QTY: _____ Refills: _____	
<input type="checkbox"/> Other: _____		QTY: _____ Refills: _____	
<input type="checkbox"/> Zeposia® Oral capsules			
Directions: Days 1-4: 0.24mg by mouth once daily, Days 5-7: 0.46mg by mouth once daily Day 8 and thereafter: 0.92mg by mouth once daily			
<input type="checkbox"/> New Patient: Zeposia starter kit (7 day starter pack followed by 30 day supply)		QTY: <u>  1 Kit (37 capsules)  </u> Refills: <u>  0  </u>	
<input type="checkbox"/> Patients restarting: 7-day titration		QTY: <u>  1 Kit (7 capsules)  </u> Refills: <u>  0  </u>	
<input type="checkbox"/> Maintenance Dose: 0.92 mg by mouth once daily		QTY: _____ Refills: _____	
<input type="checkbox"/> Other: _____		QTY: _____ Refills: _____	

Physician's Signature: \_\_\_\_\_  DAW (Dispense as Written) Date: \_\_\_\_\_

Prescriber certifies that this referral form contains an original signature and is signed by the treating physician. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send prescription on official state prescription blank. In the event requested agent is not available through AcariaHealth, this prescription shall be forwarded to an eligible pharmacy.

**IMPORTANT NOTICE:** This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.